A phase 2 trial has been conducted on the use of perioperative pembrolizumab, trastuzumab, and FLOT in patients with HER2-positive localized esophagogastric adenocarcinoma. The trial's details and findings are being reported. The treatment combination being studied involves immunotherapy and chemotherapy for a specific type of cancer.